Exubera

2006-2007 

Exubera was a revolutionary innovation for diabetics. Patients could conveniently inhale insulin rather than injecting it with a needle. It was expected to be a massive success.

But no. The inhaler was too big and inconvenient. It was also complicated to use and required extensive instructions. Exubera cost Pfizer €2,8 billion and it remains one of the costliest product failures in the history of drug development.

Additional info:

Wired.com - announcing the launch...

Forbes.com - high expectations

Forbes - Pfizer Kills Exubera